Target
cIAP1/2
2 abstracts
Abstract
Xevinapant with radiation and concurrent carboplatin and paclitaxel in patients ineligible for cisplatin with locoregionally advanced squamous cell carcinoma of the head and neck (EXtRaCT study)Org: The University of Chicago Medicine Center for Advanced Care at Orland Park, University of Michigan,
Abstract
Leveraging the mechanism of action (MOA) of xevinapant, an IAP inhibitor, for phase 3 dosing (RP3D) strategies in combination with radiation (RT) and chemoradiotherapy (CRT) in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).Org: EMD Serono Research & Development Institute, Debiopharm, Merck,